Huadong Medicine Co Ltd (000963) - Net Assets

Latest as of September 2025: CN¥24.50 Billion CNY ≈ $3.58 Billion USD

Based on the latest financial reports, Huadong Medicine Co Ltd (000963) has net assets worth CN¥24.50 Billion CNY (≈ $3.58 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥39.93 Billion ≈ $5.84 Billion USD) and total liabilities (CN¥15.43 Billion ≈ $2.26 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Huadong Medicine Co Ltd (000963) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥24.50 Billion
% of Total Assets	61.35%
Annual Growth Rate	19.27%
5-Year Change	55.23%
10-Year Change	626.53%
Growth Volatility	32.98

Huadong Medicine Co Ltd - Net Assets Trend (1997–2024)

This chart illustrates how Huadong Medicine Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Huadong Medicine Co Ltd's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for Huadong Medicine Co Ltd (1997–2024)

The table below shows the annual net assets of Huadong Medicine Co Ltd from 1997 to 2024. For live valuation and market cap data, see 000963 stock market capitalisation.

Year	Net Assets	Change
2024-12-31	CN¥23.56 Billion ≈ $3.45 Billion	+9.18%
2023-12-31	CN¥21.58 Billion ≈ $3.16 Billion	+12.55%
2022-12-31	CN¥19.18 Billion ≈ $2.81 Billion	+13.19%
2021-12-31	CN¥16.94 Billion ≈ $2.48 Billion	+11.61%
2020-12-31	CN¥15.18 Billion ≈ $2.22 Billion	+17.98%
2019-12-31	CN¥12.87 Billion ≈ $1.88 Billion	+23.41%
2018-12-31	CN¥10.43 Billion ≈ $1.53 Billion	+18.35%
2017-12-31	CN¥8.81 Billion ≈ $1.29 Billion	+15.27%
2016-12-31	CN¥7.64 Billion ≈ $1.12 Billion	+135.62%
2015-12-31	CN¥3.24 Billion ≈ $474.60 Million	+28.77%
2014-12-31	CN¥2.52 Billion ≈ $368.56 Million	-16.47%
2013-12-31	CN¥3.02 Billion ≈ $441.21 Million	+28.74%
2012-12-31	CN¥2.34 Billion ≈ $342.72 Million	+30.51%
2011-12-31	CN¥1.79 Billion ≈ $262.60 Million	+33.34%
2010-12-31	CN¥1.35 Billion ≈ $196.94 Million	+4.03%
2009-12-31	CN¥1.29 Billion ≈ $189.31 Million	+44.90%
2008-12-31	CN¥892.80 Million ≈ $130.64 Million	+30.47%
2007-12-31	CN¥684.27 Million ≈ $100.13 Million	-6.05%
2006-12-31	CN¥728.30 Million ≈ $106.57 Million	+6.01%
2005-12-31	CN¥686.99 Million ≈ $100.53 Million	+5.87%
2004-12-31	CN¥648.91 Million ≈ $94.96 Million	+1.72%
2003-12-31	CN¥637.95 Million ≈ $93.35 Million	+4.96%
2002-12-31	CN¥607.81 Million ≈ $88.94 Million	+5.15%
2001-12-31	CN¥578.05 Million ≈ $84.59 Million	+11.95%
2000-12-31	CN¥516.34 Million ≈ $75.56 Million	+2.67%
1999-12-31	CN¥502.91 Million ≈ $73.59 Million	+123.89%
1998-12-31	CN¥224.63 Million ≈ $32.87 Million	+11.14%
1997-12-31	CN¥202.11 Million ≈ $29.57 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Huadong Medicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 2549043.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥17.46 Billion	75.70%
Common Stock	CN¥1.75 Billion	7.61%
Other Components	CN¥3.85 Billion	16.69%
Total Equity	CN¥23.06 Billion	100.00%

Huadong Medicine Co Ltd Competitors by Market Cap

The table below lists competitors of Huadong Medicine Co Ltd ranked by their market capitalization.

Company	Market Cap
New Oriental Education & Technology NYSE:EDU	$8.57 Billion
ALD SA PA:AYV	$8.57 Billion
Norwegian Cruise Line Holdings Ltd NYSE:NCLH	$8.57 Billion
AKZO NOBEL SPONS.ADRS 1/3 F:AKUP	$8.57 Billion
Moog Inc NYSE:MOG-A	$8.54 Billion
Albertsons Companies NYSE:ACI	$8.54 Billion
Zhejiang Huafon Spandex Co Ltd SHE:002064	$8.54 Billion
Ryder System Inc NYSE:R	$8.53 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Huadong Medicine Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 21,047,609,756 to 23,060,051,397, a change of 2,012,441,641 (9.6%).
Net income of 3,512,104,681 contributed positively to equity growth.
Dividend payments of 1,702,177,684 reduced retained earnings.
Share repurchases of 4,133,661 reduced equity.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥3.51 Billion	+15.23%
Dividends Paid	CN¥1.70 Billion	-7.38%
Share Repurchases	CN¥4.13 Million	-0.02%
Other Changes	CN¥206.65 Million	+0.9%
Total Change	CN¥-	9.56%

Book Value vs Market Value Analysis

This analysis compares Huadong Medicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.54x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 276.94x to 2.54x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1997-12-31	CN¥0.12	CN¥33.35	x
1998-12-31	CN¥0.13	CN¥33.35	x
1999-12-31	CN¥0.30	CN¥33.35	x
2000-12-31	CN¥0.31	CN¥33.35	x
2001-12-31	CN¥0.34	CN¥33.35	x
2002-12-31	CN¥0.35	CN¥33.35	x
2003-12-31	CN¥0.37	CN¥33.35	x
2004-12-31	CN¥0.37	CN¥33.35	x
2005-12-31	CN¥0.39	CN¥33.35	x
2006-12-31	CN¥0.46	CN¥33.35	x
2007-12-31	CN¥0.37	CN¥33.35	x
2008-12-31	CN¥0.48	CN¥33.35	x
2009-12-31	CN¥0.72	CN¥33.35	x
2010-12-31	CN¥0.74	CN¥33.35	x
2011-12-31	CN¥0.98	CN¥33.35	x
2012-12-31	CN¥1.28	CN¥33.35	x
2013-12-31	CN¥1.64	CN¥33.35	x
2014-12-31	CN¥1.45	CN¥33.35	x
2015-12-31	CN¥1.90	CN¥33.35	x
2016-12-31	CN¥4.19	CN¥33.35	x
2017-12-31	CN¥4.80	CN¥33.35	x
2018-12-31	CN¥5.65	CN¥33.35	x
2019-12-31	CN¥7.03	CN¥33.35	x
2020-12-31	CN¥8.36	CN¥33.35	x
2021-12-31	CN¥9.47	CN¥33.35	x
2022-12-31	CN¥10.62	CN¥33.35	x
2023-12-31	CN¥12.02	CN¥33.35	x
2024-12-31	CN¥13.15	CN¥33.35	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Huadong Medicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 15.23%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 8.38%
• Asset Turnover: 1.11x
• Equity Multiplier: 1.64x
Recent ROE (15.23%) is below the historical average (18.57%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1997	16.19%	3.10%	1.56x	3.35x	CN¥11.62 Million
1998	14.31%	2.46%	1.65x	3.53x	CN¥8.43 Million
1999	8.53%	3.24%	1.24x	2.13x	CN¥-6.93 Million
2000	9.37%	2.79%	1.41x	2.37x	CN¥-3.03 Million
2001	10.11%	2.86%	1.52x	2.33x	CN¥584.89K
2002	8.44%	2.25%	1.51x	2.49x	CN¥-8.58 Million
2003	5.30%	1.31%	1.62x	2.49x	CN¥-27.14 Million
2004	5.26%	1.06%	1.63x	3.04x	CN¥-27.56 Million
2005	11.11%	1.93%	1.70x	3.39x	CN¥6.71 Million
2006	15.04%	2.43%	1.71x	3.62x	CN¥32.38 Million
2007	29.76%	3.57%	1.94x	4.30x	CN¥114.97 Million
2008	22.42%	2.80%	1.95x	4.11x	CN¥93.40 Million
2009	33.47%	4.84%	2.19x	3.16x	CN¥265.35 Million
2010	27.39%	3.54%	2.11x	3.67x	CN¥201.45 Million
2011	24.95%	3.43%	1.90x	3.82x	CN¥228.60 Million
2012	23.51%	3.22%	2.23x	3.27x	CN¥270.05 Million
2013	22.34%	3.44%	2.18x	2.98x	CN¥317.64 Million
2014	33.38%	3.99%	2.10x	3.97x	CN¥529.97 Million
2015	36.92%	5.05%	1.90x	3.84x	CN¥799.81 Million
2016	19.87%	5.70%	1.76x	1.99x	CN¥718.74 Million
2017	21.20%	6.39%	1.74x	1.90x	CN¥940.18 Million
2018	22.81%	7.39%	1.60x	1.93x	CN¥1.27 Billion
2019	22.85%	7.94%	1.65x	1.74x	CN¥1.58 Billion
2020	19.29%	8.37%	1.39x	1.66x	CN¥1.36 Billion
2021	13.88%	6.66%	1.28x	1.63x	CN¥643.69 Million
2022	13.45%	6.63%	1.21x	1.68x	CN¥641.42 Million
2023	13.49%	6.99%	1.21x	1.59x	CN¥734.10 Million
2024	15.23%	8.38%	1.11x	1.64x	CN¥1.21 Billion

Industry Comparison

This section compares Huadong Medicine Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $3,176,632,363
Average return on equity (ROE) among peers: 2.79%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Huadong Medicine Co Ltd (000963)	CN¥24.50 Billion	16.19%	0.63x	$8.56 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$1.06 Billion	5.59%	4.55x	$1.22 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$560.87 Million	4.60%	0.22x	$438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$9.78 Billion	0.44%	0.12x	$5.18 Billion
Livzon Pharmaceutical Group Inc (000513)	$14.31 Billion	12.41%	0.56x	$2.81 Billion
Wedge Industrial Co Ltd (000534)	$1.10 Billion	8.67%	0.93x	$2.95 Billion
Yunnan Baiyao Group Co Ltd (000538)	$184.00 Million	12.94%	0.09x	$13.85 Billion
Hainan Haiyao Co Ltd (000566)	$294.63 Million	-32.00%	2.31x	$949.23 Million
Tus Pharmaceutical Group Co Ltd (000590)	$583.33 Million	3.29%	0.50x	$391.07 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$2.55 Billion	4.67%	3.16x	$1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$1.35 Billion	7.34%	0.44x	$3.30 Billion

About Huadong Medicine Co Ltd

SHE:000963 China Drug Manufacturers - Specialty & Generic

Market Cap

$8.56 Billion

CN¥58.50 Billion CNY

Market Cap Rank

#2504 Global

#316 in China

Share Price

CN¥33.35

Change (1 day)

-0.57%

52-Week Range

CN¥33.35 - CN¥46.17

All Time High

CN¥96.84